SCHEMBL4130084

SCHEMBL4130084

COc1cccc(C(O)c2cc(C(F)(F)F)ccc2NC(=O)O)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 5/20 0.41
POLB P06746 2/20 0.39
LMNA P02545 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
SORT1 Q99523 1/20 0.39
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CTSA P10619 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2C9 P11712 1/20 0.38
HTT P42858 1/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4130147 0.88 RXFP1 (0.43) RXFP1LMNAMAPTKDM4ECTSA
SCHEMBL4109570 0.88 RXFP1 (0.45) RXFP1POLBLMNAHSD17B10USP2
SCHEMBL4129998 0.84 LPAR1 (0.48) POLBLMNAMAPTKDM4EL3MBTL1
SCHEMBL4112920 0.79 ALDH1A1 (0.45) RXFP1POLBLMNAHSD17B10USP2
SCHEMBL4116912 0.77 TAS1R3 (0.42) RXFP1LMNAHSD17B10USP2ALOX15
SCHEMBL4117574 0.76 LPAR1 (0.41) LMNATP53MAPTKDM4ECYP1A2
SCHEMBL4123131 0.76 RXFP1 (0.47) RXFP1LMNATSHRMAPTKDM4E
SCHEMBL14146416 0.74 RXFP1 (0.47) RXFP1POLBLMNATSHRMAPT
SCHEMBL4127954 0.74 NPC1 (0.41) POLBMAPTKDM4ECTSAHTT
SCHEMBL4113235 0.74 LPAR1 (0.44) MAPTKDM4EL3MBTL1LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR RXFP1 679/4885POLB 2945/4885LMNA 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.